Advertisement

Sexual Dysfunctions and Substance-Related and Addictive Disorders

  • Giovanni Martinotti
  • Emanuela Belfiglio
  • Rita Santacroce
  • Massimo di Giannantonio
Chapter
Part of the Trends in Andrology and Sexual Medicine book series (TASM)

Abstract

Substance misuse has a strict relationship with sexual dysfunctions. Psychoactive substances differently affect sexual performances in both sexes, and specific drugs and natural products are often chosen by males and females to enhance their experience and feelings before/during sexual encounters. Moreover, long-term drug users may suffer low libido, erectile dysfunction, and other sexual debilities due to the chronic effects of psychoactives on their body. A further theme of interest for mental health service workers is the intentional practice of sex under the influence of psychoactive substances, known as “chemsex,” and acted mainly among homosexual males. All these issues will be discussed in this chapter.

References

  1. 1.
    Nair R, Sellaturay S, Sriprasad S. The history of ginseng in the management of erectile dysfunction in ancient China (3500-2600 BCE). Indian J Urol. 2012;28:15–20.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Evans-Brown M, McVeigh J, Perkins C, Bellis M. Human enhancement drugs. The emerging challenges to public health. Liverpool: John Moore; 2012.Google Scholar
  3. 3.
    Jiann B. Erectile dysfunction associated with psychoactive substances. Chonnam Med J. 2008;44(3):117–24.CrossRefGoogle Scholar
  4. 4.
    Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, et al. Sex, drugs, and rock “N” roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. J Psychoactive Drugs [Internet]. 2012;44(1):38–55. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958/.CrossRefGoogle Scholar
  5. 5.
    Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Bradley KC, Boulware MB, Jiang H, Doerge RW, Meisel RL, Mermelstein PG. Changes in gene expression within the nucleus accumbens and striatum following sexual experience. Genes Brain Behav. 2005;4(1):31–44.CrossRefPubMedGoogle Scholar
  8. 8.
    McCall H, Adams N, Mason D, Willis J. What is chemsex and why does it matter? BMJ [Internet]. 2015;351:h5790. http://www.bmj.com/lookup/doi/10.1136/bmj.h5790.CrossRefGoogle Scholar
  9. 9.
    Corazza O, Martinotti G, Santacroce R, Chillemi E, Di Giannantonio M, Schifano F, et al. Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and ginkgo biloba. Biomed Res Int. 2014;2014:13.CrossRefGoogle Scholar
  10. 10.
    Pratap SA, Rajender S. Potent natural aphrodisiacs for the management of erectile dysfunction and male sexual debilities. Front Biosci (Schol Ed). 2012;4:167–80.CrossRefGoogle Scholar
  11. 11.
    Kenyon SL, Button J, Perella P, McKeown DA, Holt DW. An herbal remedy for impotence: more than was bargained for. J Clin Pharmacol. 2006;46:1379–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Gonzales GF. Ethnobiology and ethnopharmacology of lepidium meyenii (Maca), a plant from the Peruvian Highlands. Evid Based Complement Alternat Med. 2012;2012:10.CrossRefGoogle Scholar
  13. 13.
    Zheng BL, He K, Kim CH, Rogers L, Shao Y, Huang ZY, et al. Effect of a lipidic extract from lepidium meyenii on sexual behavior in mice and rats. Urology. 2000;55(4):598–602.CrossRefPubMedGoogle Scholar
  14. 14.
    Cicero AFG, Piacente S, Plaza A, Sala E, Arletti R, Pizza C. Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologia. 2002;34(3):177–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee MS, Shin B-C, Yang EJ, Lim H-J, Ernst E. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review. Maturitas. 2011;70(3):227–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Shin B-C, Lee MS, Yang EJ, Lim H-S, Ernst E. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med. 2010;10:44.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Piacente S, Carbone V, Plaza A, Zampelli A, Pizza C. Investigation of the tuber constituents of maca (Lepidium meyenii Walp.). J Agric Food Chem. 2002;50(20):5621–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Linden CH, Vellman WP, Rumack B. Yohimbine: a new street drug. Ann Emerg Med. 1985;14(10):1002–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California poison control system reported cases. Ann Pharmacother. 2010;44(6):1022–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Gass JT, Olive MF. Reinstatement of ethanol-seeking behavior following intravenous self-administration in Wistar rats. Alcohol Clin Exp Res. 2007;31(9):1441–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Feltenstein MW, See RE. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine. Behav Brain Res. 2006;174(1):1–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry. 2002;51(8):642–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Greenwald MK, Lundahl LH, Steinmiller CL. Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals. Psychopharmacology. 2013;225:811–24.CrossRefPubMedGoogle Scholar
  24. 24.
    Abad MJ, Bedoya LM, Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab. 2010;11(2):171–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Kumar S, Madaan R, Sharma A. Pharmacological evaluation of bioactive principle of Turnera aphrodisiaca. Indian J Pharm Sci. 2008;70(6):740–4.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Arletti R, Benelli A, Cavazzuti E, Scarpetta G, Bertolini A. Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology. 1999;143(1):15–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Santacroce R, Corazza O, Martinotti G, Bersani FS, Valeriani G, Di Giannantonio M. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Hum Psychopharmacol Clin Exp [Internet]. 2015;30(4):265–71.  https://doi.org/10.1002/hup.2410.CrossRefGoogle Scholar
  28. 28.
    Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, et al. Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharmacol. 2015;30(4):295–301.CrossRefPubMedGoogle Scholar
  29. 29.
    Emboden WA. Transcultural use of narcotic water lilies in ancient Egyptian and Maya drug ritual. J Ethnopharmacol. 1981;3(1):39–83.CrossRefPubMedGoogle Scholar
  30. 30.
    Fiorino DF, Phillips a G. Facilitation of sexual behavior in male rats following d-amphetamine-induced behavioral sensitization. Psychopharmacology. 1999;142(2):200–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Semple SJ, Patterson TL, Grant I. The context of sexual risk behavior among heterosexual methamphetamine users. Addict Behav. 2004;29(4):807–10.CrossRefPubMedGoogle Scholar
  32. 32.
    Palha AP, Esteves M. Drugs of abuse and sexual functioning. Adv Psychosom Med. 2008;29:131–49.CrossRefPubMedGoogle Scholar
  33. 33.
    Degenhardt L, Topp L. “Crystal meth” use among polydrug users in Sydney’s dance party subculture: characteristics, use patterns and associated harms. Int J Drug Policy. 2003;14:17–24.CrossRefGoogle Scholar
  34. 34.
    Rawson RA, Washton A, Domier CP, Reiber C. Drugs and sexual effects: role of drug type and gender. J Subst Abus Treat. 2002;22(2):103–8.CrossRefGoogle Scholar
  35. 35.
    Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7:113–39.CrossRefPubMedGoogle Scholar
  36. 36.
    Kobayashi H, Ujike H, Iwata N, Inada T, Yamada M, Sekine Y, et al. Association analysis of the tryptophan hydroxylase 2 gene polymorphisms in patients with methamphetamine dependence/psychosis. Curr Neuropharmacol. 2011;9:176–82.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs. 2001;33(3):223–32.CrossRefPubMedGoogle Scholar
  38. 38.
    Gourley M. A subcultural study of recreational ecstasy use. J Sociol. 2004;40(1):59–73.CrossRefGoogle Scholar
  39. 39.
    NIH. HSDB: 3,4-Methylenedioxymethamphetamine [Internet]. US National Library of Medicine. 2008 [cited 2017 Jan 20]. https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+@rel+42542-10-9.
  40. 40.
    Lyon RA, Glennon RA, Titeler M. 3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) [Internet]. 1986;88(4):525–6.  https://doi.org/10.1007/BF00178519.CrossRefGoogle Scholar
  41. 41.
    Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67–85.CrossRefPubMedGoogle Scholar
  42. 42.
    McElrath K. MDMA and sexual behavior: ecstasy users’ perceptions about sexuality and sexual risk. Subst Use Misuse. 2005;6084:1461–77.CrossRefGoogle Scholar
  43. 43.
    Zemishlany Z, Aizenberg D, Weizman A. Subjective effects of MDMA (“ecstasy”) on human sexual function. Eur Psychiatry. 2001;16(2):127–30.CrossRefPubMedGoogle Scholar
  44. 44.
    Breslau K. The “sextasy” craze. Clubland’s dangerous party mix: Viagra and ecstasy. Newsweek. 2002;139:30.PubMedGoogle Scholar
  45. 45.
    Tran QT, Wallace RA, Sim EHA. Priapism, ecstasy, and marijuana: is there a connection? Adv Urol. 2008;2008:193694.PubMedCentralGoogle Scholar
  46. 46.
    Romanelli F, Smith KM, Thornton AC, Pomeroy C. Poppers: epidemiology and clinical management of inhaled nitrite abuse. Pharmacotherapy. 2004;24(1):69–78.CrossRefPubMedGoogle Scholar
  47. 47.
    Lampinen TM, Mattheis K, Chan K, Hogg RS. Nitrite inhalant use among young gay and bisexual men in Vancouver during a period of increasing HIV incidence. BMC Public Health. 2007;7:35.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Gruener AM, Jeffries MAR, El Housseini Z, Whitefield L. Poppers maculopathy. Lancet. 2014;384(9954):1606.CrossRefPubMedGoogle Scholar
  49. 49.
    Romanelli F, Smith KM. Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. Ann Pharmacother [Internet]. 2004;38(6):1024–30.  https://doi.org/10.1345/aph.1D571.CrossRefGoogle Scholar
  50. 50.
    Stalnikowicz R, Amitai Y, Bentur Y. Aphrodisiac drug-induced Hemolysis. J Toxicol Clin Toxicol [Internet]. 2004;42(3):313–6.  https://doi.org/10.1081/CLT-120037435.CrossRefGoogle Scholar
  51. 51.
    Hagan IG, Burney K. Radiology of recreational drug abuse. RadioGraphics [Internet]. 2007;27(4):919–40.  https://doi.org/10.1148/rg.274065103.CrossRefGoogle Scholar
  52. 52.
    Grover S, Mattoo SK, Pendharkar S, Kandappan V. Sexual dysfunction in patients with alcohol and opioid dependence. Indian J Psychol Med. 2014;36:355–65.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Alcohol use and sexual risk behaviour: a cross-cultural study in eight countries. Geneva: World Health Organization; 2005. p. 148.Google Scholar
  54. 54.
    Arackal BS, Benegal V. Prevalence of sexual dysfunction in male subjects with alcohol dependence. Indian J Psychiatry [Internet]. 2007;49(2):109–12. http://www.ncbi.nlm.nih.gov/pubmed/20711392.CrossRefGoogle Scholar
  55. 55.
    Zaazaa A, Bella AJ, Shamloul R. Drug addiction and sexual dysfunction. Endocrinol Metab Clin N Am. 2013;42(3):585–92.CrossRefGoogle Scholar
  56. 56.
    Amoako AA, Marczylo TH, Marczylo EL, Elson J, Willets JM, Taylor AH, et al. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia. Hum Reprod. 2013;28(8):2058–66.CrossRefPubMedGoogle Scholar
  57. 57.
    Aversa A, Rossi F, Francomano D, Bruzziches R, Bertone C, Santiemma V, et al. Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. Int J Impot Res. 2008;20(6):566–73.CrossRefPubMedGoogle Scholar
  58. 58.
    Pake JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manag. 1994;9(2):126–31.CrossRefGoogle Scholar
  59. 59.
    Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect [Internet]. 2015;91(8):564–8. http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=CitingArticles&qid=1&SID=W1HnFq71TOmNoSHorBF&page=1&doc=1&cacheurlFromRightClick=no.CrossRefGoogle Scholar
  60. 60.
    Race K. “Party ‘n’ play”: online hook-up devices and the emergence of PNP practices among gay men. Sexualities. 2015:1–40.Google Scholar
  61. 61.
    Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardo FP. When “chems” meet sex: a rising phenomenon called “ChemSex”. Curr Neuropharmacol. 2016;15(5):762–70.Google Scholar
  62. 62.
    Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14(1):15–26.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone? BMJ. 2010;340:c1605.CrossRefPubMedGoogle Scholar
  64. 64.
    Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am. 2014;32(1):1–28.CrossRefPubMedGoogle Scholar
  65. 65.
    Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephedrone (4-methylmethcathinone; “meow meow”): chemical, pharmacological and clinical issues. Psychopharmacology. 2011;214(3):593–602.CrossRefPubMedGoogle Scholar
  66. 66.
    Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011;28(4):280–2.CrossRefPubMedGoogle Scholar
  67. 67.
    Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. J Clin Psychopharmacol. 2012;32(5):710–4.CrossRefPubMedGoogle Scholar
  68. 68.
    Emcdda. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone) In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances. EMCDDA Risk Assessments. 2011.Google Scholar
  69. 69.
    Newcombe R. Mephedrone: the use of mephedrone (M-cat, Meow) in Middlesbrough. Manchester: Lifeline Publications and Research; 2009. p. 1–16.Google Scholar
  70. 70.
    Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol [Internet]. 2012;50(6):458–70.  https://doi.org/10.3109/15563650.2012.702218.CrossRefGoogle Scholar
  71. 71.
    Vickers MD. Gamma hydroxybutyric acid. Clinical pharmacology and current status. Proc R Soc Med [Internet]. 1968;61(8):821–4. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1902450&tool=pmcentrez&rendertype=abstract.Google Scholar
  72. 72.
    Sumnall HR, Beynon CM, Conchie SM, Riley SCE, Cole JC. An investigation of the subjective experiences of sex after alcohol or drug intoxication. J Psychopharmacol [Internet]. 2007;21(5):525–37.  https://doi.org/10.1177/0269881106075590.CrossRefGoogle Scholar
  73. 73.
    Brewster VL, Edwards HGM, Hargreaves MD, Munshi T. Identification of the date-rape drug GHB and its precursor GBL by Raman spectroscopy. Drug Test Anal. 2009;1(1):25–31.CrossRefPubMedGoogle Scholar
  74. 74.
    Barker JC, Harris SL, Dyer JE. Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. J Psychoactive Drugs. 2007;39:115–29.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Abdulrahim D, Bowden-Jones O. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances. 2015. 335 p. http://www.drugsandalcohol.ie/24292/.
  76. 76.
    Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD, BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52–78.CrossRefPubMedGoogle Scholar
  77. 77.
    Hockenhull J, Murphy KG, Paterson S. An observed rise in γ-hydroxybutyrate-associated deaths in London: evidence to suggest a possible link with concomitant rise in chemsex. Forensic Sci Int [Internet]. 2017;270:93–7.  https://doi.org/10.1016/j.forsciint.2016.11.039.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Giovanni Martinotti
    • 1
  • Emanuela Belfiglio
    • 1
  • Rita Santacroce
    • 1
  • Massimo di Giannantonio
    • 1
  1. 1.“G.d’Annunzio” University, Department of Neuroscience, Imaging and Clinical SciencesChietiItaly

Personalised recommendations